Biotech

Biotech & Healthcare News

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 11.04.2022.

#healthcare
#clinicaltrials
#healthdata
#health
#interoperability
#cancer
#hdpalooza
#PHI
#telemedicine
#telehealth

Healthcare

@SWLifeSciences shared
On Apr 5, 2022
Can We Make a Pill to End the Pandemic? https://t.co/eEsVkp5YWz Vision and Value discusses the state of the virus & big pharma's race to slow the death rate & spread of the pandemic — and what it means for investors. $TOMDF $MRNA $PFE $BNTX $JNJ $MRK @todosmedical https://t.co/jdacCYvIbv
Open
Can We Make a Pill to End the Pandemic? Contributed Opinion

Can We Make a Pill to End the Pandemic? Contributed Opinion

Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors.

@healthythinker shared
On Apr 6, 2022
What person-centered #interoperability looks like-> @Seqster https://t.co/rqOASzmngU New OS for #healthcare de-fragments #healthdata so we can improve #health, participate in #clinicaltrials, access our #PHI & hope to outlive tough diagnoses eg #cancer @EricTopol #hdpalooza https://t.co/CJ6Reowt3A
Open
What Person-Centered Interoperability Looks Like: Seqster

What Person-Centered Interoperability Looks Like: Seqster

He had me at the statement, “I believe health data is medicine.” Those were the words of Ardy Arianpour, CEO and Co-Founder of Seqster, when sharing with me how his company was founded. ...

@LionelREICHARDT shared
On Apr 8, 2022
Upskilling in a digital health world - https://t.co/L9girq9exp
Open
Upskilling in a digital health world

Upskilling in a digital health world

It’s no secret that digital technologies are playing a significant role when it comes to shaping the next era of healthcare. Necessity accelerated the adoption of new and sophisticated ...

@MEDiSTRAVA_Cons shared
On Apr 11, 2022
RT @Abingworthbio: We are delighted to announce that Abingworth will become part of The Carlyle Group, enabling accelerated development of our strategies and funds, while expanding our geographic diversity and broadening our deal sourcing. Read more: https://t.co/4Xj1Dvty1q @OneCarlyle https://t.co/uUYUuYR2tC
Open
We are delighted to announce that Abingworth LLP will become part of The Carlyle Group

We are delighted to announce that Abingworth LLP will become part of The Carlyle Group

Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth NEW YORK, NY – Global investment firm Carlyle (NASDAQ: CG) …

@kevinmd shared
On Apr 8, 2022
RT @DigitalSalutem: If you're looking to connect with influencers that are changing the digital health industry,we suggest some here: #digitalhealth #ehealth #telehealth #healthtech #telemedicine https://t.co/RYalsQYm5L @stacy_hurt @kevinmd @daniel_kraft @LizAshallPayne @HealthEugene
Open
25 Digital Health Influencers To Follow in 2022

25 Digital Health Influencers To Follow in 2022

Connect with people that are changing digital health, this list of 25 digital health influencers to follow is a great place to start

@EUScienceInnov shared
On Apr 7, 2022
➡️On #WorldHealthDay ⚕️ let’s think of #rarediseases' patients & their families and support the work of the International Rare Diseases Research Consortium (IRDiRC)! 💪 💡Find out more about @irdirc’s work and rare diseases. 👉https://t.co/athuK9radq https://t.co/h7NLxVchpG
Open
Solving the puzzle of rare diseases through international collaboration

Solving the puzzle of rare diseases through international collaboration

  Close to 300 million people around the world have a rare disease (RD) today, but there is good reason to hope that the root causes of genetic RD – most rare diseases are genetic – will ...

@SWLifeSciences shared
On Apr 4, 2022
Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial: https://t.co/HqGf9Ddijb $NGM @NGMBio
Open
Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial Trending Company

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial Trending Company

NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid ...

@CR_UK shared
On Apr 8, 2022
Returning lung cancers might have a higher chance of being detected early - thanks to a personalised blood test. Researchers at the University of Cambridge say, liquid biopsies can be used to detect tiny amounts of remaining cancer cells after treatment 👇 https://t.co/7fvPQNlaCj
Open
Personalised blood test could help predict which lung cancers might return

Personalised blood test could help predict which lung cancers might return

Our researchers at the University of Cambridge have found that patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test.